Kalaris Therapeutics Inc. (KLRS): Earnings per share for the last twelve months

Corporate company logo of Kalaris Therapeutics (KLRS)

Kalaris Therapeutics Inc (KLRS) is developing virological pharmaceuticals through alliances with biolaboratories, which is reflected in the 12-month rolling average revenue per unit, where the value -1.83 expresses the metric level. A flawless cold chain for biomaterial delivery supports these processes; however, the clinical testing stage temporarily limits operating profit, creating minimal cash flow predictability prior to the commercialization of the drugs.

Kalaris Therapeutics Inc (KLRS) - Net earnings per share (EPS TTM) from 03/20/2025 to 11/18/2026

Summary analytical data breakdowns for Kalaris Therapeutics, Inc. (KLRS)

Analysis of all company metrics:KLRS - Kalaris Therapeutics
Mass-produced product of Kalaris Therapeutics Inc.

Annual net income per share measures capital generation efficiency relative to the total volume of issuance. By analyzing the rolling earnings per share metric, an investor can filter out market volatility. This metric is sensitive to operating losses and shareholder dilution. For Kalaris Therapeutics Inc (KLRS), the negative trend is expected due to clinical trial expenses. The absence of current revenue turns this indicator into a marker for the cash burn rate.

Competitor analysis for Kalaris Therapeutics Inc

Gilead - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Cidara Corp CDTX|Novavax Corp (NVAX) - Earnings per share for the last twelve months|CureVac N.V. - Earnings per share for the trailing year|Net earnings per share for the last 12 months VALN|Vir Biotechnology (VIR) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months SIGA Technologies Inc (SIGA)|EBS - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) AVIR (Atea Pharma)|Net earnings per share for the last four quarters Invivyd, Inc. (IVVD)|ENTA - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Inovio|HilleVax (HLVX) - Earnings per share for the last twelve months|Dyadic International Inc (DYAI) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months NanoViricides Inc.|Talphera Corp - Earnings per one share for the last 12 months|Net earnings per share for the last 12 months COCP (Cocrystal Pharma Inc)|Net earnings per share for the last four quarters Traws Therapeutics|Earnings per share for the last twelve months Dogwood Therapeutics DWTX|Net earnings per share for the trailing year Qualigen Therapeutics, Inc.|ALVR - Earnings per share for the last twelve months|vbivaccines.com (VBIV) - Net earnings per share for the last 12 months|VIRI (virios.com) - Net earnings per share for the last 12 months|VXRT - Net earnings per share for the last four quarters